Loading ...

Fast insight into nanotechnology

Access easily searchable nanoscience data, synthesis methods and literature

iron oxide nanoparticles-paclitaxel-anti-HER2/neu peptide

Based on

1 Articles
2015 Most recent source

Composition

1

ultra-small superparamagnetic iron oxide nano- particles

ultra-small superparamagnetic iron oxide nanoparticles superparamagnetic iron oxide magnetic tracer superparamagnetic iron oxide nanoparticles magnetic iron oxide nanoparticles iron oxide magnetic nanoparticles ferumoxytol nanoparticles iron oxide nanoparticles magnetic nanoparticles FeOx nano-dot centers SPIO magnetic tracer USPIO nanoparticles FexOy nanoparticles SPIO nanoparticles FeOx nanoparticles iron oxide NPs iron oxide NP Feraheme® FexOy NP FeOx NP Sienna+ IO NP SPION USPIO IONP MNP
Type Nano Material
Formula
Role core
2

polyethylene glycol

PEG
Type Polymer
Formula
Role layer
3

anti-HER2/neu peptide

AHNP
Type Biomolecule
Formula
Role layer
4

carboxymethyl-β-cyclodextrin

CM-β-CD
Type Biomolecule
Formula
Role layer
5

Paclitaxel

Abraxane Plaxicel Paxene Taxol PAC PCL PTX PX
Type Single Compound
Formula C47H51NO14
Role loaded material

Properties

General physical and chemical properties

Property Value Nanomaterial Variant Source
drug release dependent on pH

More information/entries available to subscribers only.

Or, view sample content

Applications

Area Application Nanomaterial Variant Source
drug delivery

More information available to subscribers only.

Or, view sample content

Characterization

Method Nanomaterial Variant Source
dynamic light scattering

More information available to subscribers only.

Or, view sample content

Biological effects

Preparation

Method 1

Type: Chemical synthesis
Source:
Starting materials
  • anti-HER2/neu peptide
  • phosphate buffer solution
  1. LUWaWfvFdu0M4gb
  2. dCd4WfmsFmyfqsc
  3. GB0
Product

iron oxide nanoparticles-paclitaxel-anti-HER2/neu peptide

Hydrodynamic diameter: 30.2 nm

Medium: phosphate buffer solution

Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial